Minor cannabinoids have been gathering interest among growers and extractors over the past year, with research on CBG, CBN, CBC and THC-V showing unique health benefits for consumers. But are consumers even aware of these molecules and is there demand in the marketplace? And are there genetics available that can yield enough of these minor
CBD Products & CBD Business News Exclusive Brief
This story first appeared at Marijuana Business Daily. The development of new genetic-editing technology offers cannabis companies a cost-effective way to make specific changes to marijuana and hemp plants – such as more disease resistance – without creating a genetically modified organism. The technology, known as Crispr-Cas9, will allow the cannabis industry to build new,
The Indiana state House has overwhelmingly voted to reverse a smokable hemp ban being challenged in federal court. A bill approved 69-28 last week would remove references to “smokable hemp” from the state’s 2019 law setting up hemp regulations. Those regulations banned the production and sale of hemp flower products. The bill also repeals a
An executive from international CBD brand Elixinol has been appointed to the board of directors at the U.S. Hemp Authority — one of the industry’s self-regulatory bodies. “From the start, Elixinol has gone above and beyond when it comes to product efficacy and transparency,” Elixinol CEO for the Americas Tom Siciliano said about his appointment.
North Carolina CBD maker cbdMD has hired Sibyl Swift, a former U.S. Food and Drug Administration official as a consultant to lead the company’s regulatory efforts and prepare products for certifications. Swift served in various roles at the FDA from 2014 to 2020, most notably as the associate director for research and strategy in the
(A version of this story originally appeared at Marijuana Business Daily and will be updated.) An Irish pharmaceutical firm, Jazz Pharmaceuticals, has agreed to purchase United Kingdom-based GW Pharmaceuticals, one of the largest medical cannabinoid companies in the world, for $7.2 billion, the drug companies said Wednesday. The proposed cash-and-stock deal would be the largest
